UNSPSC 51343821: Lopinavir/ritonavir

Definition: This classification denotes a combination drug for treatment of HIV. The first component, LOPINAVIR is a protease inhibitor with a US FDA Unique Ingredient Identifier of 2494G1JF75. LOPINAVIR is an International Non-Proprietary Name or INN. The second component, RITONAVIR, is a pharmacokinetic booster with a US FDA Unique Ingredient Identifier of O3J8G9O825. RITONAVIR is an International Non-Proprietary Name or INN.

UNSPSC 51343821 Lopinavir/ritonavir is a Commodity code. State and local governments show minimal recent procurement activity under this code. Of the opportunities posted in the source block, none represent actual solicitations for lopinavir/ritonavir or related antiretroviral pharmaceuticals. The single pharmaceutical-specific opportunity in the dataset—Seminole County's ITQ for Naloxone and Safe Drug Deactivation Systems (posted June 30, 2026)—addresses overdose reversal and drug disposal, not HIV treatment. The City of Tucson Fire Department's RFP for BLS/ALS pharmaceuticals and supplies (posted June 24, 2026) encompasses emergency medical drugs and equipment for prehospital care, distinct from antiretroviral therapy. A third entry, Pinellas County's ITQ for certified reference materials (drug standards for forensic analysis, posted April 23, 2026), targets laboratory calibration products, not clinical pharmaceuticals. The remaining opportunities in the block are networking events, vendor forums, reverse trade shows, grant solicitations, and consulting procurements—none soliciting lopinavir/ritonavir or related products.

The source provides no evidence of state or local government procurement for antiretroviral medications under this code in the recent period. Without documented solicitations for lopinavir/ritonavir, characterization of issuing-body types, geographic concentration, or representative contract structures is not supported by the data. Firms evaluating this code should verify whether state Medicaid agencies, public health departments, or correctional health systems are actively soliciting these products through other channels or procurement vehicles not captured in the posted opportunities reviewed here.